Neuropharmacologists examine how drugs interact with the nervous system, focusing on their effects on receptors, neurotransmitters, and enzymes in the brain. Their work is crucial in developing treatments for neurological disorders such as depression, anxiety, schizophrenia, and Parkinson’s disease. By understanding the pharmacodynamics of drugs—how they affect brain function—neuropharmacologists explore ways to enhance or inhibit specific neurochemical pathways to treat these conditions. Additionally, they study pharmacokinetics, which involves understanding how drugs are absorbed, metabolized, and eliminated by the body, to optimize drug dosages and reduce side effects. Neuropharmacologists are instrumental in advancing drug development, identifying new therapeutic targets, and designing medications with improved efficacy and fewer adverse reactions. Their expertise extends into addiction medicine, as they investigate how substances of abuse impact the brain and contribute to dependence and withdrawal symptoms. By conducting rigorous clinical trials, neuropharmacologists assess the safety and effectiveness of new medications, ensuring that patients receive the best possible treatments tailored to their needs.
Title : Novel important cellular responses, signaling mechanisms and therapeutic options in vascular dementia
Yong Xiao Wang, Albany Medical College, United States
Title : TBI updates in 2025
Jonathan Eskenazi, Cedars Sinai / UCLA, United States
Title : A case of vile vindictive primary CNS vasculitis
George Diaz, Memorial Healthcare Systems, United States
Title : Non-pharmacological strategies to counteract oxaliplatin toxicity: Protective effects of vagal nerve stimulation and resistance training on neuropathy, motor dysfunction, and muscle atrophy
Ricardo Aparecido Baptista Nucci, Hospital Sirio-Libanes, Brazil
Title : Synapticare: Integrating sleep data and tau biomarkers to assess depression severity
Medha Menon, John Foster Dulles HS, United States
Title : How have we eliminated infection: From the bone to brain?
Thomas J Webster, Interstellar Therapeutics, United States